These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18337766)

  • 21. The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways.
    Yang X; Wu X; Wu X; Huang L; Song J; Yuan C; He Z; Li Y
    Drug Des Devel Ther; 2022; 16():2545-2557. PubMed ID: 35959422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
    Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
    J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway.
    Rao Q; Xie K; Varier KM; Huang L; Song J; Yang J; Qiu J; Huang Y; Li Y; Gajendran B; Li Y; Liu S
    Front Pharmacol; 2022; 13():809551. PubMed ID: 35721186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Silencing of
    Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Expression Profiling and Protein Analysis Reveal Suppression of the C-Myc Oncogene and Inhibition JAK/STAT and PI3K/AKT/mTOR Signaling by Thymoquinone in Acute Myeloid Leukemia Cells.
    Almajali B; Johan MF; Al-Wajeeh AS; Wan Taib WR; Ismail I; Alhawamdeh M; Al-Tawarah NM; Ibrahim WN; Al-Rawashde FA; Al-Jamal HAN
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted drug delivery strategies for precision medicines.
    Manzari MT; Shamay Y; Kiguchi H; Rosen N; Scaltriti M; Heller DA
    Nat Rev Mater; 2021 Apr; 6(4):351-370. PubMed ID: 34950512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway.
    Murai Y; Jo U; Murai J; Fukuda S; Takebe N; Pommier Y
    iScience; 2021 Oct; 24(10):103173. PubMed ID: 34693224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia.
    Kaehler M; Cascorbi I
    Front Pharmacol; 2021; 12():696960. PubMed ID: 34262462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apoptosis, Autophagy, Mitophagy, Inflammation, and Necroptosis.
    Ahmad B; Gamallat Y; Khan MF; Din SR; Israr M; Ahmad M; Tahir N; Azam N; Rahman KU; Xin W; Zexu W; Linjie P; Su P; Liang W
    Onco Targets Ther; 2021; 14():1821-1841. PubMed ID: 33732000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
    Park CS; Lacorazza HD
    Exp Mol Med; 2020 Oct; 52(10):1663-1672. PubMed ID: 33067577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.
    Coltro G; Rotunno G; Mannelli L; Mannarelli C; Fiaccabrino S; Romagnoli S; Bartalucci N; Ravenda E; Gelli E; Sant'Antonio E; Patnaik MM; Tefferi A; Vannucchi AM; Guglielmelli P
    Blood Adv; 2020 Aug; 4(15):3677-3687. PubMed ID: 32777067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
    Jasek-Gajda E; Jurkowska H; Jasińska M; Lis GJ
    Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32709140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia.
    Chen S; Gan S; Han L; Li X; Xie X; Zou D; Sun H
    Ann Transl Med; 2020 Jun; 8(12):767. PubMed ID: 32647692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Berberine Induces Autophagic Cell Death in Acute Lymphoblastic Leukemia by Inactivating AKT/mTORC1 Signaling.
    Liu J; Liu P; Xu T; Chen Z; Kong H; Chu W; Wang Y; Liu Y
    Drug Des Devel Ther; 2020; 14():1813-1823. PubMed ID: 32494123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.
    Floren M; Restrepo Cruz S; Termini CM; Marjon KD; Lidke KA; Gillette JM
    Oncogene; 2020 May; 39(19):3910-3925. PubMed ID: 32203165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Mechanisms of Anticancer Activities of Puerarin.
    Ahmad B; Khan S; Liu Y; Xue M; Nabi G; Kumar S; Alshwmi M; Qarluq AW
    Cancer Manag Res; 2020; 12():79-90. PubMed ID: 32021425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling.
    Han S; Shin H; Oh JW; Oh YJ; Her NG; Nam DH
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31771104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
    Muselli F; Peyron JF; Mary D
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
    Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.